Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Whittaker

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Journal of Vascular Surgery|July 14, 2005
Restenosis in gold-coated renal artery stentsBrian W Nolan, Marc L Schermerhorn, Richard J Powell, et al.
Journal of Medicinal Chemistry|March 5, 2015
Discovery and optimization of a novel series of Dyrk1B kinase inhibitors to explore a MEK resistance hypothesisJason G Kettle, Peter Ballard, Catherine Bardelle, et al.
Journal of Medicinal Chemistry|March 16, 2012
Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generationRichard A Ward, Claire Brassington, Alexander L Breeze, et al.
Bioorganic & Medicinal Chemistry Letters|May 7, 2002
Structure-based design of peptidomimetic antagonists of p56(lck) SH2 domainChristopher J Hobbs, Rino A Bit, Andrew D Cansfield, et al.
Journal of Medicinal Chemistry|August 17, 2016
Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153)Robert H Bradbury, Rowena Callis, Gregory R Carr, et al.
Nature Chemical Biology|October 25, 2016
Potent and selective bivalent inhibitors of BET bromodomainsMichael J Waring, Huawei Chen, Alfred A Rabow, et al.
Journal of Medicinal Chemistry|May 10, 2017
Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic InhibitorsWilliam McCoull, Roman D Abrams, Erica Anderson, et al.
Journal of Medicinal Chemistry|July 18, 2017
Correction to Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic InhibitorsWilliam McCoull, Roman D Abrams, Erica Anderson, et al.
Journal of Medicinal Chemistry|October 2, 2014
Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptorM Raymond V Finlay, Mark Anderton, Susan Ashton, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Journal of Vascular Surgery|July 14, 2005
Restenosis in gold-coated renal artery stentsBrian W Nolan, Marc L Schermerhorn, Richard J Powell, et al.
Journal of Medicinal Chemistry|March 5, 2015
Discovery and optimization of a novel series of Dyrk1B kinase inhibitors to explore a MEK resistance hypothesisJason G Kettle, Peter Ballard, Catherine Bardelle, et al.
Journal of Medicinal Chemistry|March 16, 2012
Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generationRichard A Ward, Claire Brassington, Alexander L Breeze, et al.
Bioorganic & Medicinal Chemistry Letters|May 7, 2002
Structure-based design of peptidomimetic antagonists of p56(lck) SH2 domainChristopher J Hobbs, Rino A Bit, Andrew D Cansfield, et al.
Journal of Medicinal Chemistry|August 17, 2016
Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153)Robert H Bradbury, Rowena Callis, Gregory R Carr, et al.
Nature Chemical Biology|October 25, 2016
Potent and selective bivalent inhibitors of BET bromodomainsMichael J Waring, Huawei Chen, Alfred A Rabow, et al.
Journal of Medicinal Chemistry|May 10, 2017
Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic InhibitorsWilliam McCoull, Roman D Abrams, Erica Anderson, et al.
Journal of Medicinal Chemistry|July 18, 2017
Correction to Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic InhibitorsWilliam McCoull, Roman D Abrams, Erica Anderson, et al.
Journal of Medicinal Chemistry|October 2, 2014
Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptorM Raymond V Finlay, Mark Anderton, Susan Ashton, et al.
Pageof 2